Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

Abstract

PURPOSETo assess activity and toxicity of topotecan in previously treated small-cell lung cancer (SCLC) patients.PATIENTS AND METHODSPatients with measurable SCLC, progressive after one first-line ...